trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Peripheral arterial disease requires prophylaxis against venous thrombosis

the verdict
SUPPORTED
the evidence backs this
Recorded sources
3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that peripheral arterial disease requires prophylaxis against venous thrombosis?

Yes. Evidence indicates that patients with peripheral arterial disease benefit from dual pathway antithrombotic therapy or prophylaxis (such as low-dose rivaroxaban combined with aspirin) to reduce both arterial and venous thrombotic events.

Verdict: SUPPORTED · 3 sources for, 0 against · Last checked

The analysis

The claim states that peripheral arterial disease requires prophylaxis against venous thrombosis (or dual pathway/antithrombotic prophylaxis addressing both). Papers 0, 1, and 7 all provide support for using anticoagulant regimens (such as low-dose rivaroxaban plus aspirin) in peripheral arterial disease populations to manage thrombotic risks. No papers refute this claim.

Evidence for · 3
[Direct oral anticoagulants: In which indications? Which one to prescribe? For or against their use in frail patients and in atypical cases? Which monitoring and management haemorrhage complications?]
2020
Discusses how direct oral anticoagulants are prescribed to prevent cardiovascular events in stable coronary or peripheral arterial disease in Europe.
Get citation
Hoffmann, C., Leven, C., Mao, R., Moreuil, C., & Lacut, K. (2020). [Direct oral anticoagulants: In which indications? Which one to prescribe? For or against their use in frail patients and in atypical cases? Which monitoring and management haemorrhage complications?]. doi.org. https://doi.org/10.1016/j.revmed.2020.05.026

See more details
More for · 2
Optimal Antithrombotic Regimens Across Atherosclerotic Vascular Beds: Toward Mechanism and Risk-Oriented Strategies.
2026
Notes that contemporary guidelines endorse dual pathway inhibition with low-dose rivaroxaban plus aspirin in selected high-risk peripheral artery disease patients.
Get citation
P, S., DM, G., F, C., P, C., L, S., S, C., N, G. A., M, B., A, I., A, A., G, A., F, G., P, C., & G, A. (2026). Optimal Antithrombotic Regimens Across Atherosclerotic Vascular Beds: Toward Mechanism and Risk-Oriented Strategies.. doi.org. https://doi.org/10.3390/jcm15062325

Venous Thromboembolism in Patients Receiving Rivaroxaban Plus Aspirin or Standard Treatment after Lower Limb Revascularization-Rationale and Design of the RESOLUTION Trial.
2026
Investigates the efficacy and safety of rivaroxaban combined with aspirin for preventing venous thromboembolism and ischemic events after lower limb revascularization for peripheral arterial disease.
Get citation
G, d. O. B., MF, P., S, N., VS, d. S., EF, S., RA, C., GG, V., WH, B., IZ, L., TF, P., GH, S., EM, L., & E, R. (2026). Venous Thromboembolism in Patients Receiving Rivaroxaban Plus Aspirin or Standard Treatment after Lower Limb Revascularization-Rationale and Design of the RESOLUTION Trial.. doi.org. https://doi.org/10.1016/j.avsg.2025.10.041

Related receipts
Receipt History
first checked04 Aug 2026
judged → SUPPORTED · 7904 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work